Drug Comparison

Tirzepatide (Mounjaro) vs. Liraglutide (Victoza): A Comparison for Type 2 Diabetes

Both Tirzepatide (Mounjaro) and Liraglutide (Victoza) are injectable medications used to help adults and children aged 10 and older with type 2 diabetes manage their blood sugar. They work by mimicking natural hormones to improve blood sugar control. Patients often compare them due to their similar indications and mechanisms of action.

Side-by-Side Comparison

CategoryTirzepatideLiraglutide
Drug ClassGIP and GLP-1 Receptor Agonist (Dual Agonist)GLP-1 Receptor Agonist
Primary UseAdjunct to diet and exercise for glycemic control in type 2 diabetes.Adjunct to diet and exercise for glycemic control in type 2 diabetes; also reduces risk of major adverse cardiovascular events.
Mechanism of ActionMimics two natural hormones (GIP and GLP-1) to improve blood sugar control.Mimics one natural hormone (GLP-1) to improve blood sugar control.
Key AdvantageDual action on GIP and GLP-1 receptors may lead to more potent blood sugar lowering and weight loss.Proven cardiovascular benefit (reduces risk of heart attack, stroke, and cardiovascular death).
AdministrationOnce weekly injection.Once daily injection.
WarningsAcute pancreatitis, hypoglycemia with concomitant use of insulin/sulfonylurea.Acute pancreatitis, hypoglycemia with concomitant use of insulin/sulfonylurea, never share pens.
When to ChooseA doctor might prefer Tirzepatide if a patient needs more significant blood sugar lowering or weight management, as its dual action on GIP and GLP-1 receptors can be very effective. Its once-weekly dosing may also be a convenience factor for some patients.Liraglutide might be preferred for patients with type 2 diabetes who also have established cardiovascular disease, as it has a proven benefit in reducing the risk of major adverse cardiovascular events. It is also an option for those who prefer a daily injection schedule.
Side EffectsBoth medications share common side effects such as nausea, vomiting, diarrhea, and constipation, which are typical for GLP-1 receptor agonists. Both also carry a warning for acute pancreatitis and the risk of hypoglycemia when used with other blood sugar-lowering medications like insulin or sulfonylureas.
CostNeither Tirzepatide (Mounjaro) nor Liraglutide (Victoza) are currently available as generics, meaning both are brand-name drugs that can be expensive. Insurance coverage and patient assistance programs can significantly impact out-of-pocket costs for either medication.

Bottom Line

Both Tirzepatide and Liraglutide are effective injectable medications for managing type 2 diabetes, but they have key differences. Tirzepatide offers a dual-hormone approach with once-weekly dosing, while Liraglutide has established cardiovascular benefits and is given daily. The best choice depends on individual patient needs, health conditions, and treatment goals, which should be discussed with a healthcare provider.

Tirzepatide Overview

Tirzepatide is a once-weekly injectable prescription medication that activates both the GIP and GLP-1 hormone receptors — making it the first dual GIP/GLP-1 receptor agonist approved by the FDA. It is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea. Clinical trials show it reduces HbA1c by up to 2.58 percentage points and body weight by up to 20.9% at the highest dose.

Full Tirzepatide guide →

Liraglutide Overview

Liraglutide (Victoza) is a type of medicine that mimics a natural hormone in your body. It is prescribed to help adults and children aged 10 and older with type 2 diabetes manage their blood sugar levels, and it can also lower the risk of serious heart problems like heart attack or stroke in adults with type 2 diabetes and existing heart disease. It works by helping your body release insulin when needed and reducing the amount of sugar your liver makes.

Full Liraglutide guide →

Compare prices for Tirzepatide and Liraglutide

Check real-time pharmacy prices before you fill — free, no account needed.

GLP-1 Muscle Protection · Sponsored

Protect your muscle mass on GLP-1 medications

GLP-1 medications can cause up to 39% muscle loss alongside fat. Zova's AI-powered protocol — backed by Lancet Diabetes & Endocrinology research — reduces that to just 8.7% through leucine tracking and injection-day adaptive nutrition.

39%standard GLP-1
8.7%Zova Protocol
muscle loss
Join the Waitlist — Free

No credit card. No commitment.

Medical Disclaimer

The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.